About the Product

Description


Cefepime 250 mg + Tazobactam 31.25 mg Injection is a powerful combination antibiotic used for the treatment of serious and resistant bacterial infections. It is commonly prescribed for respiratory tract, urinary tract, intra-abdominal, and skin infections.

Cefepime works by inhibiting bacterial cell wall synthesis, while Tazobactam acts as a beta-lactamase inhibitor, protecting the antibiotic from degradation and enhancing its effectiveness against resistant bacteria.

This injection is widely used in hospital and critical care settings due to its broad-spectrum activity and strong clinical efficacy. It is especially useful in treating complicated and mixed bacterial infections.

Common side effects may include fever, headache, nausea, vomiting, diarrhea, and infusion-related reactions such as rash or flushing. Some patients may experience elevated liver enzymes. Rarely, hypersensitivity reactions or severe allergic responses may occur.

Cefepime 250 mg + Tazobactam 31.25 mg Injection is indicated for the treatment of serious fungal infections such as invasive candidiasis, esophageal candidiasis, and invasive aspergillosis, particularly in patients who are refractory to or intolerant of other antifungal therapies. It works by inhibiting the synthesis of the fungal cell wall, thereby controlling and eliminating infection.

This medication should be administered under strict medical supervision. Regular monitoring of liver function is recommended during treatment. Inform your doctor about any history of liver disease, allergies, or ongoing medications. Complete the full prescribed course for effective results.

Store in a cool, dry place below 25°C. Protect from light and moisture. Keep in original packaging and out of reach of children. Use as directed after reconstitution.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Tillpime TZ 281.25 Injection in the PCD pharma franchise market?

Tillpime TZ 281.25 Injection, containing Cefepime 250mg and Tazobactam 31.25mg, has strong demand in the hospital anti-infective and critical care segment, making it a high-value product for medical distributors, wholesalers, and pharma franchise partners focusing on injectable antibiotic combinations.

Why should medical distributors include Tillpime TZ 281.25 Injection in their product range?

Medical distributors and agencies can benefit from the consistent hospital demand for broad-spectrum antibiotic–beta lactamase inhibitor combinations used in severe bacterial infections, ICU cases, pneumonia, and complicated infections. Tillpime TZ 281.25 Injection helps strengthen a comprehensive critical care and anti-infective product portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for Tillpime TZ 281.25 Injection?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Tillpime TZ 281.25 Injection with promotional support, monopoly rights, quality packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for Tillpime TZ 281.25 Injection distribution?

Wholesalers and medical agencies benefit from attractive business margins, reliable product availability, professional support, and access to a trusted high-end injectable antibiotic combination range when partnering for Tillpime TZ 281.25 Injection distribution.

How can I become a distributor or franchise partner for Tillpime TZ 281.25 Injection?

Medical distributors, stockists, and wholesalers interested in Tillpime TZ 281.25 Injection can contact Cafoli LifeCare Pvt Ltd to discuss franchise opportunities, bulk supply requirements, pricing, and distribution support.